Vol.

No.

April 04, 2025Apr 04, 2025

DOWNLOAD THE PDF

Cover Story

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.

Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure

By Claire Marie Porter, Paul Goldberg and Jacquelyn Cobb

Conversation with The Cancer Letter

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed

By Jacquelyn Cobb

Guest Editorial

Rathmell: We must put the individual at the center of our approach to ending cancer

By W. Kimryn Rathmell

How City of Hope is using AI to improve surgical outcomes

By City of Hope

Free In the Archives

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

By Jacquelyn Cobb

Podcasts

In The Headlines: Private funding can’t replace federal funding—but it can help

In Brief

Alec Kimmelman announced as next CEO and Dean of NYU Langone Health

Don Dizon to join Tufts as system chief of hematology-oncology

Karen Pollok, Tim Lautenschlaeger, Jiang Bian named to leadership at IU Simon CCC

Less Radical, a podcast about Bernie Fisher, nominated for two Webby Awards

CRUK and partners pledge £5.5m funding for colorectal cancer research

University Hospitals Cleveland, Qure.ai collaborate on early lung cancer detection

MD Anderson breaks ground on new Houston-area cancer center

Clinical Roundup

Mass General study: Screenings for breast and colorectal cancer 4x higher than lung cancer

Researchers identify “master regulator” gene that could lead to more effective ovarian cancer treatment

Targeting FGFR2 may prevent or delay some KRAS-mutated pancreatic cancers

Fatty acids promote immune suppression and therapy resistance in triple negative breast cancer, Baylor Medicine study finds

Drugs & Targets

FDA approves durvalumab for muscle invasive bladder cancer

CHMP recommends approval of Calquence plus chemoimmunotherapy for first-line mantle cell lymphoma

CHMP recommends approval for Tevimbra as a first-line treatment for extensive-stage small cell lung cancer

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

NCI Trials

NCI Trials for April 2025

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 05 - February 06, 2026